JP2024516400A5 - - Google Patents

Info

Publication number
JP2024516400A5
JP2024516400A5 JP2023565513A JP2023565513A JP2024516400A5 JP 2024516400 A5 JP2024516400 A5 JP 2024516400A5 JP 2023565513 A JP2023565513 A JP 2023565513A JP 2023565513 A JP2023565513 A JP 2023565513A JP 2024516400 A5 JP2024516400 A5 JP 2024516400A5
Authority
JP
Japan
Prior art keywords
composition according
virus
item
deletion
mhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565513A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516400A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026703 external-priority patent/WO2022232375A1/en
Publication of JP2024516400A publication Critical patent/JP2024516400A/ja
Publication of JP2024516400A5 publication Critical patent/JP2024516400A5/ja
Pending legal-status Critical Current

Links

JP2023565513A 2021-04-30 2022-04-28 修飾されたmhc発現のための腫瘍溶解性ウイルス Pending JP2024516400A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182243P 2021-04-30 2021-04-30
US63/182,243 2021-04-30
PCT/US2022/026703 WO2022232375A1 (en) 2021-04-30 2022-04-28 Oncolytic viruses for modified mhc expression

Publications (2)

Publication Number Publication Date
JP2024516400A JP2024516400A (ja) 2024-04-15
JP2024516400A5 true JP2024516400A5 (cg-RX-API-DMAC7.html) 2025-05-02

Family

ID=83848828

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565513A Pending JP2024516400A (ja) 2021-04-30 2022-04-28 修飾されたmhc発現のための腫瘍溶解性ウイルス

Country Status (19)

Country Link
US (4) US12016893B2 (cg-RX-API-DMAC7.html)
EP (1) EP4329786A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024516400A (cg-RX-API-DMAC7.html)
KR (1) KR20240004764A (cg-RX-API-DMAC7.html)
CN (1) CN117241813A (cg-RX-API-DMAC7.html)
AU (1) AU2022265689A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022681A2 (cg-RX-API-DMAC7.html)
CA (1) CA3215344A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023003199A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023014507A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230551A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000233A (cg-RX-API-DMAC7.html)
EC (1) ECSP23081932A (cg-RX-API-DMAC7.html)
IL (2) IL308018B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20230257A1 (cg-RX-API-DMAC7.html)
MX (2) MX2023012608A (cg-RX-API-DMAC7.html)
PE (1) PE20250454A1 (cg-RX-API-DMAC7.html)
TW (1) TW202305125A (cg-RX-API-DMAC7.html)
WO (1) WO2022232375A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115927471A (zh) * 2022-11-23 2023-04-07 郑州大学 A49r基因缺失的溶瘤痘苗病毒载体的构建方法及应用
JP2025541309A (ja) * 2022-12-15 2025-12-18 カリヴィル イムノセラピューティクス, インコーポレイテッド Cd47/sirp-アルファ免疫チェックポイント阻害剤の組成物およびその使用
WO2025184411A1 (en) * 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
WO2025199630A1 (en) * 2024-03-27 2025-10-02 Genvira Biosciences Inc. Viruses for inducing antigen presentation
WO2026107113A1 (en) * 2024-11-12 2026-05-21 Calidi Biotherapeutics (Nevada), Inc. MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4409450A (en) 1982-07-29 1983-10-11 Amp Incorporated Double pole membrane switch having preferred sequence closing feature
IL71275A0 (en) 1983-03-21 1984-06-29 Sparamedica Ag Human interleukin-2-and its preparation
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993021173A1 (en) 1992-04-17 1993-10-28 Abbott Laboratories Taxol derivatives
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
CA2144040A1 (fr) 1993-07-13 1995-01-26 Michel Perricaudet Vecteurs adenoviraux defectifs et utilisation en therapie genique
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
CA2309688C (en) 1997-11-10 2007-04-24 Cellegy Pharmaceuticals, Inc. Penetration enhancing and irritation reducing systems
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AT406376B (de) 1998-01-16 2000-04-25 Immuno Ag Chimäres poxvirus enthaltend eine retrovirale vektorkomponente
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6198323B1 (en) 1999-01-28 2001-03-06 Lucent Technologies Inc. Flip-flop having gated inverter feedback structure with embedded preset/clear logic
US20040214783A1 (en) 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
KR100880765B1 (ko) 2000-03-14 2009-02-02 버베리안 노딕 에이/에스 변형된 백시니아 바이러스 안카라(mva)의 변형 균주
JP2003526367A (ja) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Rna干渉の方法とrna干渉組成物
DE60116075T4 (de) 2000-04-25 2007-06-06 Immunex Corp., Thousand Oaks Behandlung von tumoren mit photodynamischer therapie
US7179483B2 (en) 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US7030099B2 (en) 2000-07-21 2006-04-18 Research Corporation Technologies, Inc. Tumor specific promoters of the midkine gene that allow for selective expression in P53-inactivated cells
AU2002211490A1 (en) 2000-10-04 2002-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
EP1213025A1 (de) 2000-12-06 2002-06-12 Laboratoires Serobiologiques(Societe Anonyme) Kosmetische und/oder dermopharmazeutische Zubereitungen enthaltend Extrakte aus den Blättern der Pflanze Argania spinosa
EP1341817A2 (en) 2000-12-08 2003-09-10 Novo Nordisk A/S Tff peptides
WO2002092134A1 (en) 2001-05-14 2002-11-21 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
JP2003009883A (ja) 2001-07-05 2003-01-14 Mitsubishi Pharma Corp マスト細胞の細胞死誘発剤
AU2002350409A1 (en) 2001-10-26 2003-05-06 Uffe Holmskov Surfactant protein-d and atherosclerosis
US7368122B1 (en) 2002-03-08 2008-05-06 Dow Pharmaceutical Sciences Skin cream
WO2004014314A2 (en) 2002-08-12 2004-02-19 David Kirn Methods and compositions concerning poxviruses and cancer
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US20040143026A1 (en) 2002-12-31 2004-07-22 Shah Kishore R. Bioadhesive hydrophilic composition for treatment of mammalian skin
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
JP4719855B2 (ja) 2003-12-05 2011-07-06 国立大学法人北海道大学 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター
DE102004030044A1 (de) 2004-06-22 2006-01-12 Birken Gmbh Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels
ES2433467T3 (es) 2005-01-20 2013-12-11 Isconova Ab Composición de vacuna que comprende una proteína de unión a fibronectina o un péptido de unión a fibronectina
WO2008023077A2 (en) 2006-08-25 2008-02-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Compositions and methods for modulating an immune response
DK2402451T3 (en) 2006-08-25 2018-06-25 The Government Of The Us Secretary Department Of Health And Human Services Method for Stabilizing a DNA Insert in a Recombinant Vaccine Vector
EP2415783B1 (en) * 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
GB0702695D0 (en) 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
US8003363B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
EP2484691B1 (en) 2007-07-10 2016-01-13 Apogenix GmbH TNF superfamily collectin fusion proteins
CN101970650B (zh) 2008-03-06 2017-07-25 哈洛齐梅公司 可溶性透明质酸酶的大规模生产
PT2119726E (pt) * 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
US10603351B2 (en) 2008-08-21 2020-03-31 Turnstone Limited Partnership Engineered synergistic oncolytic viral symbiosis
CN101381742A (zh) 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
EP2184297A1 (en) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G polypeptides and pharmaceutical uses thereof
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
CA2709292A1 (en) 2009-07-10 2011-01-10 The Governors Of The University Of Alberta Oncolytic viruses and methods for treating neoplastic disorders
EP2617426B1 (en) 2010-09-17 2016-08-10 Japan Science and Technology Agency Inhibitor of hmgb protein-mediated immune response activation
WO2012089225A1 (en) * 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
US9919047B2 (en) 2011-01-04 2018-03-20 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
EP2697368B1 (en) * 2011-04-15 2019-06-05 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
KR102022952B1 (ko) 2011-08-05 2019-09-20 신라젠(주) 백시니아 바이러스의 생산을 위한 방법 및 조성물
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9862932B2 (en) 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
EP3461491B1 (en) 2013-04-18 2024-11-13 TILT Biotherapeutics Oy Enhanced adoptive cell therapy
KR102322510B1 (ko) * 2013-07-18 2021-11-08 브이아이비 브이지더블유 수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인
ES2847305T3 (es) 2013-08-22 2021-08-02 Univ Pittsburgh Commonwealth Sys Higher Education Terapias inmunooncolíticas
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
MA39818A (fr) * 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
US20160060313A1 (en) 2014-08-27 2016-03-03 Daewoong Jo Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Angiogenic Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Angiogenic Compositions Comprising the Same
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
EP3217993A1 (en) 2015-07-20 2017-09-20 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
HK1255192A1 (zh) 2015-09-08 2019-08-09 Sillajen, Inc. 表达细胞因子和羧酸酯酶的修饰的溶瘤痘苗病毒及其使用方法
CN109152815B (zh) 2016-02-25 2022-10-18 纪念斯隆凯特琳癌症中心 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
US20180000733A1 (en) 2016-06-30 2018-01-04 Ava, Inc. Safe and stable antiseptic solution comprising chlorhexidine
CA3070146A1 (en) * 2016-07-19 2018-01-25 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oncolytic viruses targeting stat3
JP2019528753A (ja) 2016-09-21 2019-10-17 スティーブン エイチ. ソーン, 高移動度グループboxi突然変異体
US20200046784A1 (en) 2016-09-30 2020-02-13 University Health Network Recombinant oncolytic viruses for cancer therapy
WO2018091680A1 (en) * 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
US11185586B2 (en) 2016-11-22 2021-11-30 Alloplex Biotherapeutics, Inc. Allogeneic tumor cell vaccine
WO2018111902A1 (en) * 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
US20200268831A1 (en) * 2017-09-15 2020-08-27 The Texas A&M University System Methods for enhancing immunotherapy in the treatment of cancer
WO2019089755A1 (en) * 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
JP2021509815A (ja) * 2018-01-05 2021-04-08 オタワ ホスピタル リサーチ インスティチュート 改変ワクシニアベクター
JP2021511060A (ja) 2018-01-26 2021-05-06 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現
CA3099330A1 (en) * 2018-05-02 2019-11-07 Tonix Pharma Holdings Limited Synthetic chimeric vaccinia virus
CA3112654A1 (en) * 2018-09-15 2020-03-19 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
CA3116192C (en) * 2018-11-06 2025-09-23 Calidi Biotherapeutics (Nevada), Inc. IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
KR20220004959A (ko) * 2019-02-27 2022-01-12 액팀 테라퓨틱스, 인코퍼레이티드 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아

Similar Documents

Publication Publication Date Title
US10660947B2 (en) Vaccine composition
EP2212423B1 (en) Poxviral oncolytic vectors
JP2021527694A5 (cg-RX-API-DMAC7.html)
JP2025160281A (ja) 個別化ワクチン
Li et al. Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review
JP2021500932A5 (cg-RX-API-DMAC7.html)
CN101868474A (zh) 痘病毒溶瘤载体
CA3045228C (en) Oncolytic viruses and therapeutic molecules
JP2020531524A5 (cg-RX-API-DMAC7.html)
BR112020003669A2 (pt) terapia de combinação para tratamento do câncer com administração intravenosa de um mva recombinante e de um anticorpo
JP2024516400A (ja) 修飾されたmhc発現のための腫瘍溶解性ウイルス
JP2023552289A5 (cg-RX-API-DMAC7.html)
CN113840914B (zh) 诱导细胞融合的痘苗病毒及其应用
JP6657115B2 (ja) ポックスウイルス腫瘍細胞崩壊性ベクター
JP2025188115A (ja) 新規遺伝子組換えワクシニアウイルス及びその利用
US9687515B2 (en) Poxviral oncolytic vectors
HK40103886A (en) Oncolytic viruses for modified mhc expression
WO2024130212A1 (en) Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors
HK40012869A (en) Oncolytic viruses and therapeutic molecules
Gaston Potential roles of the immunostimulatory signals IL-15 and mica in oncolytic HSV-1 therapy for malignant glioma